GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Loans Receivable

Sutro Biopharma (FRA:S09) Loans Receivable : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Loans Receivable?

Sutro Biopharma's Loans Receivable for the quarter that ended in Mar. 2024 was €0.0 Mil.


Sutro Biopharma Loans Receivable Historical Data

The historical data trend for Sutro Biopharma's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Loans Receivable Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Sutro Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sutro Biopharma Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Sutro Biopharma Loans Receivable Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma (FRA:S09) Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma (FRA:S09) Headlines

No Headlines